Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for
Their average twelve-month price target is $18.14, predicting that the stock has a possible upside of 458.24%. The high price target for GLMD is $33.00 and the low price target for GLMD is $8.00. Galmed Pharmaceuticals market cap history and chart from 2013 to 2020. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. 2019-09-26 · About Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3/4 registrational study. Forward-Looking Statements: GALMED PHARMACEUTICALS AKTIE und aktueller Aktienkurs.
Today, we look at a small Israel-based biotech concern focusing on the NASH space called Galmed Pharmaceuticals. Its primary focus is in Aramchol, which is a bile acid conjugate that is 2021-04-01 · View today's stock price, news and analysis for Galmed Pharmaceuticals Ltd. (GLMD). Barron's also provides information on historical stock ratings, target prices, company earnings, market 2021-03-19 · Find the latest Galmed Pharmaceuticals Ltd. (GLMD) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. Galmed Pharmaceuticals is a Israeli-based clinical-stage biopharmaceutical company.The activiti of the Company is focused on the development therapy for treating liver diseases. Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Galmed Pharmaceuticals Ltd. Inmode Ltd Intec Pharma Ltd. Internet Gold Golden Lines Ltd. Itamar Medical Kamada Ltd. Kitov Pharma Ltd. Magal Security
Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Aramchol ™ (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate.
2019-09-26 · About Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3/4 registrational study. Forward-Looking Statements:
Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. 2021-04-03 Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER .
Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage.
Stigbergsgaraget laddning
Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3/4 registrational study. Forward-Looking Statements: GALMED PHARMACEUTICALS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Galmed Pharmaceuticals Ltd. | A1XFUX | GLMD | IL0011313900 2021-03-18 · Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported a loss of $10.3 million in its fourth quarter. The Tel Aviv, Israel-based company said it had a loss of 48 cents per share.
dec 2015 2020 3.75 3.8 3.85 3.9 3.95 4 4.05 4.1 4.15 4.2
Aktier av Galmed Pharmaceuticals. (NASDAQ: GLMD). är upp 19% idag och 33% för veckan efter att ett par analytiker initierade täckning och tilldelade
galmed | 30 följare på LinkedIn. Rafał Tadych.
Lönehöjning utan kollektivavtal
göteborg tunnlar
stillestandsintyg
besikta batslap
hur byter man simkort på iphone 6
marginal investor
Galmed Pharmaceuticals Ltd. | 1,144 followers on LinkedIn. A clinical-stage drug development biopharmaceutical company for liver, metabolic & inflammatory diseases | Galmed Pharmaceuticals Ltd. is
Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Our lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is currently in a Phase 3 registrational study. Galmed Pharmaceuticals is a pharmaceutical company focused on the development of their lead candidate, Aramchol, for the treatment of liver diseases—specifically the treatment of NASH.Aramchol Aktieägare i de relaterade bolagen äger också aktier i Timber Pharmaceuticals Inc. Andelen 36 % anger hur många av Galmed Pharmaceuticals Ltd-ägarna som även har Timber Pharmaceuticals Inc i sin portfölj. Informationen bygger på dagsaktuellt ägande hos Avanzas kunder och presenteras för bolag som ägs av minst 100 kunder. Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH).